Anbio Biotechnology Class A Ordinary Shares
NASDAQ:NNNN · NASDAQ Global Select
+$0.37 today
Vol 0.02M · Avg 0.03M
Balance Sheet
Inspect the capital base behind the business
Review assets, liabilities, equity, cash, and debt to judge whether the company has the financial position to support future returns.
Balance Sheet
Assets, liabilities & equity
| Cash & Equivalents | $7.8M |
| Short-term Investments | $4.1M |
| Receivables | $3.7M |
| Other Current | $14.7M |
| Total Current Assets | $30.2M |
| Total Assets | $30.2M |
Analysis
Selected assets total $30.2M for Latest. The largest visible component is Other Current at $14.7M, about 48.6% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.
Balance Sheet
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $7.8M -34.0% | $11.8M +21.4% | $9.7M +36.4% | $7.1M +69.9% | $4.2M | $1.0B | $841.8M | $673.8M |
| Short-term Investments | $4.1M | $0 | $0 -100.0% | $1.6M | $0 | -$1.6B | $445.6M | $378.4M |
| Net Receivables | $3.7M +243.4% | $1.1M -43.5% | $1.9M +52537.8% | $3.6K -99.5% | $717.5K | $533.8M | $399.4M | -$1.7B |
| Inventory | $0 | $0 | $0 -100.0% | $353.9K | $0 | $641.6M | $328.0M | $316.8M |
| Other Current Assets | $0 | $0 | $0 | $0 | $0 | $1.5B | $966.4M | $764.8M |
| Total Current Assets | $30.2M +63.2% | $18.5M +17.7% | $15.7M +13.0% | $13.9M +183.6% | $4.9M | $12.5B | $10.5B | $5.5B |
| Property, Plant & Equipment (Net) | $0 | $0 | $0 -100.0% | $12.1K | $0 | $1.2B | $1.5B | $687.8M |
| Goodwill | $0 | $0 | $0 | $0 | $0 | $925.8M | $466.6M | $309.8M |
| Intangible Assets | $0 | $0 | $0 | $0 | $0 | $568.8M | $860.0M | $1.5B |
| Long-term Investments | $0 | $0 | $0 | $0 | $0 | $524.0M | -$1.5B | $860.0M |
| Tax Assets | $0 | $0 | $0 | $0 | $0 | $1.5B | $1.4B | $1.4B |
| Other Non-current Assets | $0 -100.0% | $387.4K +523.5% | $62.1K +1978.9% | $3.0K | $0 | $1.4B | $1.0B | $679.4M |
| Total Non-current Assets | $0 -100.0% | $387.4K +523.5% | $62.1K +312.9% | $15.0K | $0 | -$15.3B | $14.8B | $11.3B |
| Total Assets | $30.2M +59.8% | $18.9M +19.7% | $15.8M +13.3% | $14.0M +184.0% | $4.9M | $13.3B | $11.9B | $10.6B |
| Account Payables | $0 -100.0% | $1.6M +96.5% | $827.2K -41.3% | $1.4M -25.5% | $1.9M | $1.3B | -$1.5B | $1.4B |
| Short-term Debt | $0 | $0 | $0 | $0 | $0 | -$1.6B | -$1.6B | $326.6M |
| Tax Payables | $0 | $0 | $0 | $0 | $0 | $574.4M | -$1.5B | $1.4B |
| Deferred Revenue | $0 | $0 | $0 | $0 -100.0% | $490.0K | -$1.6B | $374.2M | $542.2M |
| Other Current Liabilities | $0 | $0 | $0 | $0 | $0 | $1.1B | $1.5B | $493.2M |
| Total Current Liabilities | $87.8K -94.9% | $1.7M +74.2% | $993.1K -29.6% | $1.4M -40.7% | $2.4M | $6.0B | $10.1B | $14.3B |
| Long-term Debt | $0 | $0 | $0 | $0 | $0 | $1.3B | $438.6M | $1.3B |
| Deferred Tax Liabilities | $0 | $0 | $0 | $0 | $0 | $746.6M | $612.2M | $477.8M |
| Deferred Revenue (Non-current) | $0 | $0 | $0 | $0 | $0 | -$1.6B | $715.8M | $1.3B |
| Other Non-current Liabilities | $0 | $0 | $0 | $0 | $0 | $489.0M | $1.1B | -$1.5B |
| Total Non-current Liabilities | $0 | $0 | $0 | $0 | $0 | $3.9B | $7.5B | $14.1B |
| Total Liabilities | $87.8K -94.9% | $1.7M +74.2% | $993.1K -29.6% | $1.4M -40.7% | $2.4M | $14.7B | $3.7B | $9.6B |
| Common Stock | $14.4K +1.1% | $14.2K +0.0% | $14.2K | $0 | $0 | $651.4M | $517.0M | $382.6M |
| Retained Earnings | $23.6M +37.3% | $17.2M +16.0% | $14.8M +18.0% | $12.5M +394.8% | $2.5M | -$1.6B | $519.8M | $1.1B |
| Accumulated OCI | $0 | $0 | $0 | $0 | $0 | $393.8M | $550.6M | $707.4M |
| Other Stockholders Equity | $0 | $0 | $0 | $0 | $0 | $351.8M | -$1.6B | $1.5B |
| Minority Interest | $0 | $0 | $0 | $0 | $0 | $1.4B | $337.8M | $931.4M |
| Total Equity | $30.2M +75.4% | $17.2M +16.0% | $14.8M +18.1% | $12.5M +394.8% | $2.5M | $9.1B | $7.7B | $3.3B |
| Total Debt | $0 | $0 | $0 | $0 | $0 | $724.2M | $410.6M | $399.4M |
| Net Debt | -$7.8M +34.0% | -$11.8M -21.4% | -$9.7M -36.4% | -$7.1M -69.9% | -$4.2M | $389.6M | $501.6M | $311.2M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
KalVista Pharmaceuticals, Inc.
NASDAQ:KALV
$1.44B
Avanos Medical, Inc.
NYSE:AVNS
$1.17B
COMPASS Pathways plc
NASDAQ:CMPS
$1.16B
Talkspace, Inc.
NASDAQ:TALK
$872.74M
Rigel Pharmaceuticals, Inc.
NASDAQ:RIGL
$604.74M
ClearPoint Neuro, Inc.
NASDAQ:CLPT
$537.11M
AngioDynamics, Inc.
NASDAQ:ANGO
$492.52M
Community Health Systems, Inc.
NYSE:CYH
$429.09M
SNDL Inc.
NASDAQ:SNDL
$367.05M
Gossamer Bio, Inc.
GOSS
$39.12M
SEC Filings
Recent regulatory filings
No filings found.
How much cash does NNNN have?
Anbio Biotechnology Class A Ordinary Shares (NNNN) reported $7.77M in cash and equivalents in fiscal 2025.
How much debt does NNNN carry?
Anbio Biotechnology Class A Ordinary Shares (NNNN) reported $0.00 of total debt, with net debt of -$7,766,738.00.
Explore More
Continue the stock analysis
Jump to another research area for this company.